A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, Jr., Freemantle, N., Mason, J., Eccles, M., & Boynton, J. (1999) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 107
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 25
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Items 201–300 of 510
Anti-inflammatory drugs as potential antimicrobial agents: a review
Okpala, O. E., Rondevaldová, J., & Kokoška, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1557333 · Cited by 23
Drug-Induced Stuttering: Occurrence and Possible Pathways
Ekhart, C., van Hunsel, F. P. A. M., van Harten, P. N., van Baarsen, J., Yingying, T., & Bast, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.692568 · Cited by 19
Sharma, S., Archie, S. R., Kanchanwala, V., Mimun, K., Rahman, M. A., Zhang, Y., & Abbruscato, T. J. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.886099 · Cited by 18
Neurotransmitter receptor density changes in Pitx3ak mice – A model relevant to Parkinson’s disease
Cremer, J. N., Amunts, K., Graw, J., Piel, M., Rösch, F., & Zilles, K. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.050 · Cited by 19
“H-ligands, non-radioactive displacers and incubation conditions of the autoradiographic experiments Receptor 3 H-ligand, amount in main incubation 20 min, 22 °C 45 min, 22 °C H]prazosin, [ 3 H]UK 14,304, [ 3 H]8-OH-DPAT, [ 3 H]ketanserin , [ 3 H]SCH 23390, [ 3 H]ZM 241385, [ 3 H]fallypride and [ 3 H ]raclopride bindin…”
InfluentialNovel Pharmacological Approaches to Drug Abuse Treatment
Edens, E. L., Massa, A. A., & Petrakis, I. L. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_29 · Cited by 22
“As such, its side effect profile differs from other antidepressants with diminished weight gain and sexual dysfunction (Stahl et al. 2004).”
BackgroundPrimary and Secondary Prevention of Lung Cancer
Kathuria, H., & Neptune, E. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.002 · Cited by 18
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
“of abuse, such as nicotine, methamphetamines, cocaine, and so forth [75,77,78].”
BackgroundFurman, J. L., Soyombo, A. A., Czysz, A. H., Jha, M. K., Carmody, T. J., Mason, B. L., Scherer, P. E., & Trivedi, M. H. (2018) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2018.05.001 · Cited by 21
How to manage cigarette smoking in kidney transplant candidates and recipients?
Devresse, A., Gohy, S. T., Robert, A., & Kanaan, N. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab072 · Cited by 16
Lambrechts, M. J., D’Antonio, N. D., Toci, G. R., Karamian, B. A., Pezzulo, J. D., Farronato, D. M., Canseco, J. A., Kaye, I. D., Woods, B. I., Rihn, J. A., et al. (2023) · Asian Spine Journal · doi:10.31616/asj.2022.0065 · Cited by 16
“Instead of targeting serotonin reuptake, bupropion dually targets norepinephrine and dopamine reuptake, giving it unique antidepressant properties [27].”
BackgroundIdentification of non‐reported bupropion metabolites in human plasma
Connarn, J. N., Luo, R., Windak, J., Zhang, X., Babiskin, A. H., Kelly, M., Harrington, G. J., Ellingrod, V. L., Kamali, M., McInnis, M. G., et al. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2046 · Cited by 16
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders
Englisch, S., Jung, H. S., Lewien, A., Becker, A., Nowak, U., Braun, H., Thiem, J., Eisenacher, S., Meyer‐Lindenberg, A., & Zink, M. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000587 · Cited by 16
Howard, P. D., Twycross, R., Shuster, J. L., Mihalyo, M., & Wilcock, A. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.09.001 · Cited by 18
Zhang, T., Zou, P., Fang, Y., & Li, Y. (2022) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2335 · Cited by 16
Clinical neuroscience of amphetamine-type stimulants
Courtney, K. E., & Ray, L. A. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.010 · Cited by 17
“and norepinephrine reuptake inhibitor (Stahl et al., 2004), bupropion also acts as a noncompetitive antagonist of several neuronal nicotinic acetylcholine (nACh) receptors (Slemmer et al.”
BackgroundA case of bupropion-induced stuttering
Fetterolf, F., & Marceau, M. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.07.003 · Cited by 16
“At clinically relevant doses, it is a dual norepinephrine (NE) and dopamine (DA) reuptake inhibitor [12].”
BackgroundBupropion for the treatment of seasonal affective disorder
Niemegeers, P., Dumont, G. J. H., Patteet, L., Neels, H. M., & Sabbe, B. G. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.804062 · Cited by 19
“However, as bupropion increases dopamine concentrations in the synapse, albeit with a rather modest potency [44], it may have some abuse potential in higher dosages.”
BackgroundBehavioral Reactivity and Addiction: The Adaptation of Behavioral Response to Reward Opportunities
Trafton, J. A., & Gifford, E. V. (2008) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20.1.23 · Cited by 15
Marks, C., Silvola, R. M., Teal, E., Quinney, S. K., & Haas, D. M. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2628 · Cited by 17
Leone, F. T., & Evers‐Casey, S. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.011 · Cited by 18
Cadeddu, R., Ibba, M., Sadile, A. G., & Carboni, E. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3335-y · Cited by 19
Rzepa, E., Dean, Z., & McCabe, C. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx016 · Cited by 15
“…negative are flattened (Price et al., 2009), whereas catecholamine antidepressants like bupropion (dopamine and noradrenaline reuptake inhibitor) (Stahl et al., 2004; Dwoskin et al., 2006) might be more efficacious at improving anhedonia in depression (Dunlop and Nemeroff, 2007; Nutt et al.,…”
Wellbutrin®: Misuse and Abuse by Incarcerated Individuals
Phillips, D. (2012) · Journal of Addictions Nursing · doi:10.3109/10884602.2011.647838 · Cited by 16
Nicholson, E. R., Dilley, J. E., & Froehlich, J. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13577 · Cited by 17
“The mechanism by which BUPmay work to decrease alco- hol intake is not clear, but there is a general consensus that BUP increases extracellular concentrations of both DA and NE in the NAc by weakly blocking their respective transporters DAT and NET (Nomikos et al., 1989, 1992; Stahl et al., 2004).”
Rianprakaisang, T. N., Prather, C. T., Lin, A. L., Murray, B. P., Hendrickson, R. G., & on behalf of the Toxicology Investigators Consortium (ToxIC) (2021) · Clinical Toxicology · doi:10.1080/15563650.2021.1913180 · Cited by 15
“In contrast to many other antidepressant medications, bupropion does not inhibit serotonin reuptake [5,7] but may increase serotoninergic neuronal firing [8,9] and has been implicated”
ResultVismara, M. E. M., Benatti, B., Nicolini, G., Cova, I., Monfrini, E., Fonzo, A. D., Fetoni, V., Viganò, C. A., Priori, A., & Dell’Osso, B. M. (2022) · BMC Neurology · doi:10.1186/s12883-022-02668-4 · Cited by 15
“However, Bupropion lacks typical antidepressantassociated side effects such as sexual dysfunction, weight gain, and sedation [56].”
BackgroundPark, Y. M., Lee, H., Kang, S., Cho, J.-H., & Kim, L. (2009) · Psychiatry Investigation · doi:10.4306/pi.2009.6.4.313 · Cited by 15
Dash, R. P., Rais, R., & Srinivas, N. R. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1376765 · Cited by 15
“This effect was consistent with an elevation in synaptic levels of dopamine and norepinephrine which subsequently impeded neuronal firing via an autoreceptor-mediated negative feedback mechanism (Stahl et al., 2004).”
BackgroundResultCarney, G., Bassett, K. L., Maclure, M., Taylor, S., & Dormuth, C. R. (2020) · Addiction · doi:10.1111/add.14951 · Cited by 17
Poleszak, E., Wośko, S., Sławińska, K., Wyska, E., Szopa, A., Świąder, K., Wróbel, A., Szponar, J., Doboszewska, U., Właź, P., et al. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00088-0 · Cited by 15
Slyepchenko, A., Brunoni, A. R., McIntyre, R. S., Quevedo, J., & Carvalho, A. F. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160126144601 · Cited by 14
Bupropion-Induced Myoclonus: Case Report and Review of the Literature
Riaz, A., Ali, H. T., Allahham, A., Caprara, A. L. F., & Rissardo, J. P. (2023) · The Neurohospitalist · doi:10.1177/19418744231173283 · Cited by 14
“Thus, common antidepressant-associated side effects such as sexual dysfunction, sedation, and weight gain are not associated with bupropion therapy.(4) The typical antidepressants such as fluoxetine, venlafaxine, or paroxetine are well-known to cause sexual dysfunction as a side effect.”
BackgroundDagher, M., Cahill, C. M., & Andrews, A. M. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100046 · Cited by 16
“Bupropion acts as a reuptake inhibitor at dopamine and norepinephrine transporter (Stahl et al, 2004).”
Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia
Chen, J., Su, Y. A., Wang, S. L., Bian, Q., Liu, Y. H., Wang, N., Yang, F. D., Haile, C. N., Kosten, T. R., & Zhang, X. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08l04671 · Cited by 14
Overcoming barriers to disseminate effective smoking cessation treatments globally
Patwardhan, S., & Rose, J. E. (2020) · Drugs and Alcohol Today · doi:10.1108/dat-01-2020-0001 · Cited by 15
Viana, A. F., Rates, S. M. K., Naudin, B., Janin, F., Costentin, J., & do-Rego, J.-C. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082898 · Cited by 18
Maron, E., Eller, T., Vasar, V., & Nutt, D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08l04477 · Cited by 14
Bupropion improved apathy in behavioral variant frontotemporal dementia: a case report
Lin, C., Chu, C.-P., & Liu, H. (2016) · Neurocase · doi:10.1080/13554794.2016.1211711 · Cited by 14
“Bupropion is currently the only available antidepressant which has a selective effect to increase dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex by dopamine reuptake inhibition (Stahl et al., 2004).”
BackgroundBupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations
Stuebler, A. G., & Jansen, M. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.118349 · Cited by 14
“Bupropion’s therapeutic effect is thought to be mediated by the blocked reuptake of dopamine and norepinephrine (Stahl et al., 2004) and the noncompetitive inhibition of neuronal and muscular AChRs (Slemmer et al., 2000).”
BackgroundSeizures After Overdoses of Bupropion Intake
Kara, H., Ak, A., Bayır, A., Acar, D., Istanbulluoglu, R., & Değirmenci, S. (2012) · Balkan Medical Journal · doi:10.5152/balkanmedj.2012.094 · Cited by 14
A 5-Year Follow-Up of Diabetes Knowledge in Persons With Serious Mental Illness and Type 2 Diabetes
Dickerson, F., Kreyenbuhl, J. A., Goldberg, R. W., Fang, L., Medoff, D. R., Brown, C. H., & Dixon, L. B. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08l04602 · Cited by 14
Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD
Dagan, Y., & Yager, J. (2018) · International Journal of Eating Disorders · doi:10.1002/eat.22948 · Cited by 13
Ľupták, M., Fišar, Z., & Hroudová, J. (2023) · Antioxidants · doi:10.3390/antiox12061208 · Cited by 17
Zainol, M., Sidi, H., Kumar, J., Das, S., Ismail, S. B., Hatta, M. H., Baharuddin, N., & Ravindran, A. V. (2017) · Current Drug Targets · doi:10.2174/1389450118666170315110902 · Cited by 15
Sumithrarachchi, S., Jayasinghe, R. D., & Warnakulasuriya, S. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1963990 · Cited by 14
“Similarly, Bupropion may prove to be having a therapeutic effect for BQ dependence through higher dopamine levels (Stahl et al., 2004) similar to the action of arecoline through MAO-A pathway, but yet to be tested with clinical trials.”
BackgroundNukitram, J., Cheaha, D., Sengnon, N., Wungsintaweekul, J., Limsuwanchote, S., & Kumarnsit, E. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114824 · Cited by 14
Peters, E. M., Balbuena, L., & Lodhi, R. J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.066 · Cited by 13
Weekly ethanol exposure alters dopaminergic parameters in zebrafish brain
Alexandre, M. C. M., Mendes, N. V., Torres, C. A., Baldin, S. L., Bernardo, H. T., Scussel, R., Baggio, S., Mussulini, B. H. M., Zenki, K. C., da Rosa, M. I., et al. (2019) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2019.106822 · Cited by 16
Pharmacogenetics of Obesity Drug Therapy
Guzman, A. K., Ding, M., Xie, Y., & Martin, K. A. (2014) · Current Molecular Medicine · doi:10.2174/1566524014666140811120307 · Cited by 12
Studt, A., Gannon, M. K., Orzel, J. A., Vaughan, A., & Pearlman, A. M. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-210039 · Cited by 13
“Bupropion, another atypical antidepressant, may indirectly affect transport of serotonin via vesicular monoamine transporter-2 (VMAT2) [9].”
A mechanistic overview of approaches for the treatment of psychostimulant dependence
Jensen, K. L., Jensen, S. B., & Madsen, K. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854176 · Cited by 14
“Interestingly, bupropion has no appreciable affinity for postsynaptic receptors of neither histamine, dopamine, acetylcholine or epinephrine (Stahl et al., 2004).”
BackgroundD1R-5-HT2AR Uncoupling Reduces Depressive Behaviours via HDAC Signalling
Li, W., Ali, T., Mou, S., Gong, Q., Li, N., Hao, L., Yu, Z., & Li, S. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01436-7 · Cited by 12
“Clinical tests also indicated that the effects of SSRIs could be augmented by the dopamine and noradrenaline reuptake inhibitor bupropion [18], suggesting that D1R is necessary for the therapeutic effects of SSRIs.”
BackgroundInteraction of bupropion and zinc with neuronal nicotinic acetylcholine receptors
García‐Colunga, J., Godoy-García, U., & Vázquez-Gómez, E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.009 · Cited by 13
“Specifically, bupropion interacts with noradrenaline and dopamine transporters as well as with a variety of nAChR subtypes, inhibiting their functions (Arias, 2009; Slemmer et al., 2000; Stahl et al., 2004).”
BackgroundGetting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 16
“83,87,89 The elimination rate is strongly affected by CYP2D6 polymorphism.”
InfluentialGatch, M. B., & Forster, M. J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120914213 · Cited by 12
“For example, bupropion acts at NET and DAT and as a nicotinic acetylcholine receptor antagonist (Arias et al., 2009; Damaj et al., 2004; Stahl et al., 2004), which contributes to its efficacy as an antidepressant and smoking cessation treatment.”
BackgroundBupropion-associated movement disorders: A systematic review
Rissardo, J. P., & Caprara, A. L. F. (2020) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_35_19 · Cited by 14
Modeling Decision-Making Systems in Addiction
Kurth-Nelson, Z. L., & Redish, A. D. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0751-5_6 · Cited by 14
Bupropion XL–Induced Motor and Vocal Tics
Kayhan, F., Uğuz, F., Kayhan, A., & Toktaş, İ. F. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000056 · Cited by 12
“Particularly, bupropion increases dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex.(20) Tics after bupropion administration may originate from increased dopaminergic activation in the striatum caused by the aforementioned drug.”
BackgroundBhattacharjee, M., & Perumal, E. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.07.010 · Cited by 13
Varela, R. B., Macpherson, H. K., Walker, A. J., Houghton, T., Yates, C. G., Yates, N. J., Daygon, V. D., & Tye, S. J. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.001 · Cited by 13
“Bupropion is an aminoketone antidepressant which acts by weakly inhibiting reuptake of DA and norepinephrine, with efficacy similar to classical antidepressants (Stahl, 2004).”
Ramli, F. F., Azizi, M. H., & Hashim, S. A. S. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.57641 · Cited by 11
“Serotonin enhancement is related to sexual dysfunction in patients on SSRIs [38].”
BackgroundSafety Profile of Bremelanotide Across the Clinical Development Program
Clayton, A. H., Kingsberg, S. A., Portman, D. J., Sadiq, A., Krop, J. S., Jordan, R., Lucas, J. D., & Simon, J. A. (2022) · Journal of Women s Health · doi:10.1089/jwh.2021.0191 · Cited by 11
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression
Cook, J. T., & Halaris, A. E. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110603 · Cited by 12
Serotonin Syndrome in a Patient on Tramadol, Bupropion, Trazodone, and Oxycodone
Falls, B. A., & Gurrera, R. J. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.05.013 · Cited by 11
Carrasco, M. C., Vidal, J., & Redolat, R. (2013) · Behavioural Processes · doi:10.1016/j.beproc.2013.05.002 · Cited by 13
Ziprasidone-Induced Angioedema: A Case Report
Mohan, T. S., Bastiampillai, T. J., & Dhillon, R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07l04657 · Cited by 11
Reimets, R., Raud, S., Loomets, M., Visnapuu, T., Volke, V., Reimets, A., Plaas, M., & Vasar, E. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.04.011 · Cited by 15
IUPHAR review – Data-driven computational drug repurposing approaches for opioid use disorder
Gao, Z., Ding, P., & Xu, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106960 · Cited by 11
Vas deferens neuro-effector junction: From kymographic tracings to structural biology principles
Navarrete, L. C., Barrera, N. P., & Huidobro-Toro, J. P. (2014) · Autonomic Neuroscience · doi:10.1016/j.autneu.2014.05.010 · Cited by 11
Zahiroddin, A., Farıdhosseını, F., Zamani, A., & Shahini, N. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.24998 · Cited by 11
“This drug can be used in reinforcing the effect of SSRI drugs or reducing drug side effects such as sexual side effects (8, 9).”
BackgroundInfluentialMore than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 14
“However, a conflicting report suggests that after properly adjusting for bias, there is no indication that use of any nicotine replacement formulation improves outcomes for smoking cessation over placebo (Stanley and Massey, 2016).”
BackgroundNaglich, A. C., Brown, E. S., & Adinoff, B. H. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545023 · Cited by 12
Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease
Wang, H. J., Chinna‐Meyyappan, A., Feldman, O. J., & Lanctôt, K. L. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2363215 · Cited by 12
“Bupropion is also a norepinephrine and dopamine reup-take inhibitor (NDRI), which may help alleviate NPS such as depression [56].”
Kim, E. J., Felsövályi, K., Young, L. M., Shmelkov, S. V., Grunebaum, M. F., & Cardozo, T. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4958-9 · Cited by 10
Müller, L. G., Stolz, E. D., Betti, A. H., Herzfeldt, V., & Rates, S. M. K. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12396 · Cited by 10
O'Byrne, P., Williams, R., Walsh, J. J., & Gilmer, J. F. (2014) · Pharmaceuticals · doi:10.3390/ph7050595 · Cited by 11
“It is a dopamine and norepinephrine reuptake inhibitor [1] and a nicotinic acetylcholine receptor antagonist [2].”
BackgroundUmezu, T., & Shibata, Y. (2016) · Toxicology Reports · doi:10.1016/j.toxrep.2016.06.005 · Cited by 11
Degradation of Bupropion: Implications for Interpretation of Postmortem Case Data
Bishop-Freeman, S. C., Hensel, E. M., Feaster, M. S., & Winecker, R. E. (2018) · Journal of Analytical Toxicology · doi:10.1093/jat/bky058 · Cited by 10
Epileptic seizures, coma and EEG burst‐suppression from suicidal bupropion intoxication
Noda, A. H., Schu, U., Maier, T., Knake, S., & Rosenow, F. (2017) · Epileptic Disorders · doi:10.1684/epd.2017.0896 · Cited by 12
Periodic limb movements in sleep in patients using antidepressants
Marey, H., Chai, A., & Bikov, A. (2024) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2024.102011 · Cited by 10
Gómez, C., Carrasco, C., & Redolat, R. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00099.x · Cited by 10
“A dual mechanism of action has been proposed for bupropion, the central one being an inhibition of the reuptake of both dopamine and norepinephrine (Cooper, Hester & Maxwel 1980; Ferris, Cooper & Maxwell 1983; Ascher et al. 1995; Stahl et al. 2004).”
BackgroundMoreira, R. F., Rigato, H. M., & Borges, B. C. (2009) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000016 · Cited by 10
“Bupropion, a norepinephrine/dopamine reuptake inhibitor (NDRI) (Stahl et al., 2004), has been available in the United States for the treatment of major depressive disorder since 1989.”
BackgroundRoncero, C., Abad, A. C., Padilla-Mata, A., Ros‐Cucurull, E., Barral, C., Casas, M., & Grau‐López, L. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160324144912 · Cited by 9
“Dopamine (DA) is a neurotransmitter which participates in various cognitive functions, such as attention and concentration [1].”
Bupropion-Related Exacerbation of Tic Disorder in an Adult: A Case Report
Lurie, I., Ganor, O., & Mayer, G. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000312 · Cited by 9
“Bupropion's neuropharmacological activity has been shown to involve inhibition of the reuptake of dopamine.(1) Animal studies have indicated that bupropion may induce stereotypical motor behaviors.”
BackgroundRecent advancements in pharmacological strategies to modulate energy balance for combating obesity
Pati, B., Sendh, S., Sahu, B., Pani, S., Jena, N., & Bal, N. C. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00107e · Cited by 10
Impact of the antidepressant Bupropion on the Dynamic Energy Budget of Daphnia magna
Chaabani, S., Einum, S., Jaspers, V. L. B., Asimakopoulos, A. G., Zhang, J., & Muller, E. B. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.164984 · Cited by 9
Brain energy metabolism is increased by chronic administration of bupropion
Ferreira, G. K., Rezin, G. T., Cardoso, M. R., Gonçalves, C. L., Borges, L. S., Vieira, J. S., Gomes, L. M., Zugno, A. I., Quevedo, J., & STRECK, E. L. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00597.x · Cited by 9
“Thus, it is possible that bupropion may modulate other neurotransmitters in addition to monoamines (8).”
BackgroundBhattacharya, C. S., Kirby, D., Stipdonk, M. J. V., & Stratford, R. E. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0516-4 · Cited by 10
Does Bupropion Impact More than Mood? A Case Report and Review of the Literature
Yasin, W., Ahmed, S. I., & Gouthro, R. V. (2019) · Cureus · doi:10.7759/cureus.4277 · Cited by 9
Dopamine mediates life-history responses to food abundance in Daphnia
Issa, S., Gamelon, M., Ciesielski, T. M., Vike-Jonas, K., Asimakopoulos, A. G., Jaspers, V. L. B., & Einum, S. (2020) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2020.1069 · Cited by 12
“Bupropion inhibits the neuronal reuptake of norepinephrine and dopamine, increasing their concentration in the synaptic cleft [25].”
BackgroundLee, H. G., Kwon, Y., & Chun, Y.-J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01581-x · Cited by 10
Tabah, A., Gold, L. S., Marcum, Z. A., & Hansen, R. N. (2023) · Pharmacoepidemiology · doi:10.3390/pharma2030018 · Cited by 8
“The clinical significance of the magnitude of the observed hazard ratios must be interpreted with the potential significance of a fall injury for an older adult, which can be debilitating.”
BackgroundMokhtar, H. I., Zaitone, S. A., El-Sayed, K., Lashine, R. M., Ahmed, N., Moursi, S. M. M., Shehata, S. A., Aldahish, A. A., Helal, M. A., El-Kherbetawy, M. K., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17111436 · Cited by 9
Ireland, D., Rabeler, C., Rao, S., Richardson, R. J., & Collins, E. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315394 · Cited by 8
Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders
Nestsiarovich, A., Mazurie, A., Hurwitz, N. G., Kerner, B., Nelson, S. J., Crisanti, A. S., Tohen, M. F., Krall, R. L., Perkins, D. J., & Lambert, C. G. (2018) · Bipolar Disorders · doi:10.1111/bdi.12665 · Cited by 8
Effect of comedication of bupropion and other antidepressants on body mass index
Ravindran, P. P., Zang, W., Renukunta, S., Mansour, R., & Denduluri, S. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315577057 · Cited by 8
Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion
Boreu, Q. F., Coll-Negre, M., Serra, M., & Cavalleria-Verdaguer, M. (2018) · Clinics and Practice · doi:10.4081/cp.2018.1044 · Cited by 10
Keith, K. M., Geller, J. A., Froehlich, A., Arfken, C. L., Oxley, M., & Mischel, N. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001542 · Cited by 8
“Bupropion, which is often used in atypical depression, as an adjunct to SSRIs, or as a second line for major depression may work in a similar way, suppressing NE and dopamine reuptake, thus making more catecholamines available in the synapse.(33) It is possible NE and dopaminergic activity during the infusion and/or r…”
BackgroundBupropion-Induced Acute Dystonia with Dose Escalation and Use of Naranjo Nomogram
Wasif, N., Wasif, K., & Saif, M. W. (2017) · Cureus · doi:10.7759/cureus.1157 · Cited by 8
“Common adverse effects include dry mouth, nausea, insomnia, headache, anxiety, tremor, dizziness, and constipation [1-2] (Table 1).”
BackgroundAladeen, T. S., Westphal, E. S., Lee, Y. L., Rong, C., Rainka, M. M., Capote, H. A., & McIntyre, R. S. (2018) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12258 · Cited by 8
“However, a higher numberof adverse eventswasobservedwithbupropion treatment (12) than with brexpiprazole treatment (7) (p = 0.”
Background
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.